Microbial landscape in hospital patients with new coronavirus disease (COVID-19), antibiotic resistance comparison vs. Pre-covid stage: a prospective study

Background. The new coronavirus infection has manifested untypically compared to other acute respiratory agents, posing a major challenge to researchers worldwide. Despite low incidence of bacterial complications, microbial coinfection plays an important role in the onset and development of severe COVID-19 to hamper diagnosis, treatment and prognosis.

Objectives. A study of microbial landscape in secondary complications of COVID-19 and prevailing microbial-agent antibiotic resistance dynamics in COVID-19 vs. patients with pre-COVID community-acquired pneumonia.

Methods. We analysed 1,113 bacterial sputum cultures in COVID-19 patients from 21 hospital of Krasnodar Krai. The study sample comprised 524 strains isolated from COVID-19 patients in bacteriological assays. The comparison sample included 643 positive sputum strains isolated from community-acquired pneumonia patients developing disease in outcome of acute respiratory infection in 2015–2018. The microbial aetiology landscape and strain antibiotic resistance have been compared in COVID-19 vs. patients with community-acquired pneumonia.

Results. Gram-negative bacteria predominated in COVID-19 cultures (58%), followed by Gram-positive bacteria (15%) and fungi (27%). Acinetobacter baumannii (35%) and Klebsiella pneumoniae (33%) were about equally represented in Gram-negative flora, Pseudomonas aeruginosa (19%) and other microorganisms were half as common. Streptococcus pneumonia and Staphylococcus aureus accounted for 48 and 15% Gram-positive strains, respectively. Sputum-isolated fungi were mainly identifi ed as Candida albicans (89%). The Streptoccocus pneumoniae detection rate dropped to 7% in 2020 relative of other flora, which is 10 times less vs. pre-COVID rates, whilst the fungal rate increased dramatically. Antibiotic resistance increased in most isolated microbial strains.

Conclusion. A Gram-negative-dominated aetiology of lower respiratory tract lesions, as well as higher risk of fungal and other opportunistic coinfections should be taken into account in patient treatment for a complicated coronavirus infection. A higher antibiotic resistance is induced by active indication-ignorant use of antibiotics, including pre-hospital treatment. A suitable treatment regimen in COVID-19 should avoid undue antibiotic prescriptions in every patient.

1. Zhu X., Ge Y., Wu T., Zhao K., Chen Y., Wu B., Zhu F., Zhu B., Cui L. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020; 285: 198005. DOI: 10.1016/j.virusres.2020.198005

2. Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis. J. Infect. 2020; 81(2): 266–275. DOI: 10.1016/j.jinf.2020.05.046

3. Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFadden D.R., Soucy J.R., Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta- analysis. Clin. Microbiol. Infect. 2020; 26(12): 1622–1629. DOI: 10.1016/j.cmi.2020.07.016

4. Garcia-Vidal C., Sanjuan G., Moreno-García E., Puerta-Alcalde P., Garcia-Pouton N., Chumbita M., Fernandez- Pittol M., Pitart C., Inciarte A., Bodro M., Morata L., Ambrosioni J., Grafi a I., Meira F., Macaya I., Cardozo C., Casals C., Tellez A., Castro P., Marco F., García F., Mensa J., Martínez J.A., Soriano A.; COVID-19 Researchers Group. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin. Microbiol. Infect. 2021; 27(1): 83–88. DOI: 10.1016/j.cmi.2020.07.041

5. Mahmoudi H. Bacterial co–infections and antibiotic resistance in patients with COVID-19. GMS Hyg Infect Control. 2020 Dec 17;15: Doc35. DOI: 10.3205/ dgkh000370. PMID: 33391970. PMCID: PMC7747008

6. Fattorini L., Creti R., Palma C., Pantosti A.; Unit of Antibiotic Resistance and Special Pathogens; Unit of Antibiotic Resistance and Special Pathogens of the Department of Infectious Diseases, Istituto Superiore di Sanità, Rome. Bacterial coinfections in COVID-19: an underestimated adversary. Ann. Ist. Super Sanita. 2020; 56(3): 359–364. DOI: 10.4415/ANN_20_03_14

7. Manohar P., Loh B., Nachimuthu R., Hua X., Welburn S.C., Leptihn S. Secondary Bacterial Infections in Patients With Viral Pneumonia. Front. Med. (Lausanne). 2020; 7: 420. DOI: 10.3389/fmed.2020.00420

8. Hughes S., Troise O., Donaldson H., Mughal N., Moore L.S.P. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin. Microbiol. Infect. 2020; 26(10): 1395–1399. DOI: 10.1016/j.cmi.2020.06.025

9. Lai C.C., Yu W.L. COVID-19 associated with pulmonary aspergillosis: A literature review. J. Microbiol. Immunol. Infect. 2021; 54(1): 46–53. DOI: 10.1016/j.jmii.2020.09.004

10. Chen X., Liao B., Cheng L., Peng X., Xu X., Li Y., Hu T., Li J., Zhou X., Ren B. The microbial coinfection in COVID-19. Appl. Microbiol. Biotechnol. 2020; 104(18): 7777–7785. DOI: 10.1007/s00253-020-10814-6

11. Youngs J., Wyncoll D., Hopkins P., Arnold A., Ball J., Bicanic T. Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with infl uenza. J. Infect. 2020; 81(3): e55–e57. DOI: 10.1016/j.jinf.2020.06.056

12. Rothe K., Feihl S., Schneider J., Wallnöfer F., Wurst M., Lukas M., Treiber M., Lahmer T., Heim M., Dommasch M., Waschulzik B., Zink A., Querbach C., Busch D.H., Schmid R.M., Schneider G., Spinner C.D. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur. J. Clin. Microbiol. Infect. Dis. 2021; 40(4): 859–869. DOI: 10.1007/s10096-020-04063-8

13. Munch M.W., Meyhoff T.S., Helleberg M., Kjaer M.N., Granholm A., Hjortsø C.J.S., Jensen T.S., Møller M.H., Hjortrup P.B., Wetterslev M., Vesterlund G.K., Russell L., Jørgensen V.L., Tjelle Kristiansen K., Benfi eld T., Ulrik C.S., Andreasen A.S., Bestle M.H., Poulsen L.M., Hildebrandt T., Knudsen L.S., Møller A., Sølling C.G., Brøchner A.C., Rasmussen B.S., Nielsen H., Christensen S., Strøm T., Cronhjort M., Wahlin R.R., Jakob S.M., Cioccari L., Venkatesh B., Hammond N., Jha V., Myatra S.N., Jensen M.Q., Leistner J.W., Mikkelsen V.S., Svenningsen J.S., Laursen S.B., Hatley E.V., Kristensen C.M., Al-Alak A., Clapp E., Jonassen T.B., Bjerregaard C.L., Østerby N.C.H.,Jespersen M.M., Abou-Kassem D., Lassen M.L., Zaabalawi R., Daoud M.M., Abdi S., Meier N., la Cour K., Derby C.B., Damlund B.R., Laigaard J., Andersen L.L., Mikkelsen J., Jensen J.L.S., Rasmussen A.H., Arnerlöv E., Lykke M., Holst-Hansen M.Z.B., Tøstesen B.W., Schwab J., Madsen E.K., Gluud C., Lange T., Perner A. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta. Anaesthesiol. Scand. 2021. DOI: 10.1111/aas.13941

14. Falavigna M., Colpani V., Stein C., Azevedo L.C.P., Bagattini A.M., Brito G.V., Chatkin J.M., Cimerman S., Corradi M.F.D.B., Cunha C.A.D., Medeiros F.C., Oliveira Junior H.A., Fritscher L.G., Gazzana M.B., Gräf D.D., Marra L.P., Matuoka J.Y., Nunes M.S., Pachito D.V., Pagano C.G.M., Parreira P.C.S., Riera R., Silva A. Júnior, Tavares B.M., Zavascki A.P., Rosa R.G., Dal-Pizzol F. Guidelines for the pharmacological treatment of COVID–19. The task–force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. Rev. Bras. Ter. Intensiva. 2020; 32(2): 166–196. DOI: 10.5935/0103-507x.20200039

15. Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., Satta G., Cooke G., Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. 2020; 71(9): 2459–2468. DOI: 10.1093/cid/ciaa530

16. Mirzaei R., Goodarzi P., Asadi M., Soltani A., Aljanabi H.A.A., Jeda A.S., Dashtbin S., Jalalifar S., Mohammadzadeh R., Teimoori A., Tari K., Salari M., Ghiasvand S., Kazemi S., Yousefi mashouf R., Keyvani H., Karampoor S. Bacterial co-infections with SARS-CoV-2. IUBMB Life. 2020; 72(10): 2097–2111. DOI: 10.1002/iub.2356

17. Sultana J., Cutroneo P.M., Crisafulli S., Puglisi G., Caramori G., Trifi rò G. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. Drug. Saf. 2020; 43(8): 691–698. DOI: 10.1007/s40264-020-00976-7

18. Rawson T.M., Wilson R.C., Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin. Microbiol. Infect. 2021; 27(1): 9–11. DOI: 10.1016/j.cmi.2020.09.025

19. Avdeeva M.G., Shubina G.V., Ganzha A.A., Zhuravleva E.V. Community-acquired pneumonia in infectious hospital patients: the development of resistance to antimicrobials. Epidemiology and Infectious Diseases. 2018; 23(3): 108–113 (In Russ., English abstract). DOI: 10.18821/1560-9529-2018-23-3-108-113

20. Sharifi pour E., Shams S., Esmkhani M., Khodadadi J., Fotouhi-Ardakani R., Koohpaei A., Doosti Z., Ej Golzari S. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect. Dis. 2020; 20(1): 646. DOI: 10.1186/s12879-020-05374-z

21. Svistushkin V.M., Nikiforova G.N., Artamonova P.S. Antibacterial therapy for ENT diseases during the COVID-19 pandemic. Consilium Medicum. 2020; 22 (11): 10–15 (In Russ., English abstract). DOI: 10.26442/20751753.2020.11.200359